RE: NTCD M331 Jan 2024 14:49
John it states in the RNS any further trials for M3 are at the expense of Sabela
“This may include a further Phase 2 study to de-risk Phase 3 study. As previously announced, Sebela has the right, at its own cost, to complete any further trials.”